JO3772B1 - صيغة جسم مضاد لـ cgrp - Google Patents
صيغة جسم مضاد لـ cgrpInfo
- Publication number
- JO3772B1 JO3772B1 JOP/2016/0111A JOP20160111A JO3772B1 JO 3772 B1 JO3772 B1 JO 3772B1 JO P20160111 A JOP20160111 A JO P20160111A JO 3772 B1 JO3772 B1 JO 3772B1
- Authority
- JO
- Jordan
- Prior art keywords
- antibody formulation
- cgrp antibody
- headaches
- episodic
- chronic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
يتعلق الاختراع الحالي بصيغ صيدلية لأجسام مضادة لـ CGRP، وطرق استخدامها، حيث تكون نافعة كعلاج لأنواع الصداع النصفي، أنواع الصداع العارض، أنواع الصداع المزمن، أنواع الصداع العنقودي المزمن، وأنواع الصداع العنقودي العارض.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562180905P | 2015-06-17 | 2015-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3772B1 true JO3772B1 (ar) | 2021-01-31 |
Family
ID=56131672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2016/0111A JO3772B1 (ar) | 2015-06-17 | 2016-06-05 | صيغة جسم مضاد لـ cgrp |
Country Status (21)
Country | Link |
---|---|
US (3) | US11498959B2 (ar) |
EP (1) | EP3310809A1 (ar) |
JP (1) | JP6438599B2 (ar) |
KR (1) | KR102000867B1 (ar) |
CN (2) | CN114948847A (ar) |
AR (1) | AR104847A1 (ar) |
AU (1) | AU2016280555B2 (ar) |
BR (1) | BR112017023374A2 (ar) |
CA (1) | CA2984185A1 (ar) |
EA (1) | EA037580B1 (ar) |
HK (1) | HK1245813A1 (ar) |
IL (2) | IL292562A (ar) |
JO (1) | JO3772B1 (ar) |
MA (1) | MA49726A (ar) |
MX (1) | MX2017016199A (ar) |
MY (1) | MY184266A (ar) |
NZ (1) | NZ737046A (ar) |
TW (1) | TWI725973B (ar) |
UA (1) | UA120881C2 (ar) |
WO (1) | WO2016205037A1 (ar) |
ZA (1) | ZA201707324B (ar) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
JP6568099B2 (ja) | 2014-03-21 | 2019-08-28 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH | カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法 |
EP3515488A1 (en) * | 2016-09-23 | 2019-07-31 | Teva Pharmaceuticals International GmbH | Treating cluster headache |
BR112019005823A2 (pt) | 2016-09-23 | 2019-06-25 | Teva Pharmaceuticals Int Gmbh | tratamento para enxaqueca refratária |
JP7195262B2 (ja) | 2017-03-02 | 2022-12-23 | ベス イスラエル デアコネス メディカル センター インコーポレイティッド | カルシトニン遺伝子関連ペプチドを指向する抗体に応答性の頭痛患者の選択方法 |
TWI754772B (zh) * | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
AR114722A1 (es) * | 2018-04-02 | 2020-10-07 | Amgen Inc | Composiciones de erenumab y usos de las mismas |
WO2019231800A1 (en) * | 2018-05-31 | 2019-12-05 | Eli Lilly And Company | Anti-cgrp antibodies for treating menstrual-related migraines |
WO2020146527A1 (en) | 2019-01-08 | 2020-07-16 | Alder Biopharmaceuticals, Inc. | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
MA55815A (fr) * | 2019-05-02 | 2022-03-09 | H Lundbeck As | Traitement de céphalées à l'aide d'anticorps anti-cgrp |
US20240139171A1 (en) | 2021-03-02 | 2024-05-02 | Cgrp Diagnostics Gmbh | Treatment and/or reduction of occurrence of migraine |
WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100303872B1 (ko) | 1992-10-02 | 2001-11-22 | 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 | 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법 |
TW518219B (en) | 1996-04-26 | 2003-01-21 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
PT1441589E (pt) * | 2001-11-08 | 2012-08-13 | Abbott Biotherapeutics Corp | Formulação farmacêutica líquida estável de anticorpos igg |
MY162623A (en) | 2003-02-10 | 2017-06-30 | Biogen Ma Inc | Immunoglobulin formulation and method of preparation thereof |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
CA2595380A1 (en) * | 2005-01-28 | 2006-08-03 | Wyeth | Stabilized liquid polypeptide formulations |
US20090238820A1 (en) * | 2005-03-08 | 2009-09-24 | Allan Corey M | ANTI-MAdCAM ANTIBODY COMPOSITIONS |
US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
AU2006344395B2 (en) * | 2005-10-13 | 2013-05-02 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive diseases |
RS57194B1 (sr) | 2005-11-14 | 2018-07-31 | Teva Pharmaceuticals Int Gmbh | Antagonistička antitela specifična za peptid koji je u vezi sa genom za kalcitonin za lečenje klaster glavobolje |
WO2007123765A2 (en) | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
CN101553504A (zh) * | 2006-12-11 | 2009-10-07 | 豪夫迈·罗氏有限公司 | Aβ抗体胃肠外制剂 |
US20090060906A1 (en) * | 2007-01-09 | 2009-03-05 | Wyeth | Anti-IL-13 antibody formulations and uses thereof |
CA2681743A1 (en) * | 2007-03-22 | 2008-09-25 | Imclone Llc | Stable antibody formulations |
RU2491094C2 (ru) | 2007-03-30 | 2013-08-27 | Медиммун, Ллк | Препарат антитела |
RU2523894C2 (ru) * | 2007-04-18 | 2014-07-27 | Янссен Альцгеймер Иммунотерапи | Предупреждение и лечение церебральной амилоидной ангиопатии |
SI2331090T1 (en) * | 2008-09-19 | 2018-04-30 | Pfizer Inc. | Stable liquid antibody formulation |
US9393304B2 (en) | 2008-10-29 | 2016-07-19 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
CA2743469C (en) * | 2008-11-12 | 2019-01-15 | Medimmune, Llc | Antibody formulation |
NZ592644A (en) * | 2008-11-28 | 2013-09-27 | Abbott Lab | Stable antibody compositions and methods for stabilizing same |
EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
CA2754266A1 (en) * | 2009-03-06 | 2010-09-10 | Medimmune, Llc | Humanized anti-cd19 antibody formulations |
JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
AR081434A1 (es) * | 2010-06-10 | 2012-08-29 | Lilly Co Eli | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo |
ES2850973T3 (es) * | 2010-08-23 | 2021-09-01 | Wyeth Llc | Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis |
LT2691112T (lt) * | 2011-03-31 | 2018-07-25 | Merck Sharp & Dohme Corp. | Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai |
LT3495392T (lt) * | 2011-05-20 | 2021-09-27 | H. Lundbeck A/S | Anti-cgrp kompozicijos ir jų panaudojimas |
US9803009B2 (en) | 2011-10-24 | 2017-10-31 | Abbvie Inc. | Immunobinders directed against TNF |
US20140227250A1 (en) * | 2012-08-23 | 2014-08-14 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
BR112015017619A2 (pt) * | 2013-01-24 | 2017-11-21 | Glaxosmithkline Ip Dev Ltd | formulação líquida, uso de uma formulação, e, kit |
JP6568099B2 (ja) * | 2014-03-21 | 2019-08-28 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH | カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法 |
-
2016
- 2016-06-01 AR ARP160101603A patent/AR104847A1/es unknown
- 2016-06-02 TW TW105117447A patent/TWI725973B/zh active
- 2016-06-05 JO JOP/2016/0111A patent/JO3772B1/ar active
- 2016-06-08 US US15/578,263 patent/US11498959B2/en active Active
- 2016-06-08 CA CA2984185A patent/CA2984185A1/en active Pending
- 2016-06-08 KR KR1020177035870A patent/KR102000867B1/ko active Protection Beyond IP Right Term
- 2016-06-08 MA MA049726A patent/MA49726A/fr unknown
- 2016-06-08 EP EP16729483.4A patent/EP3310809A1/en active Pending
- 2016-06-08 CN CN202210229605.2A patent/CN114948847A/zh active Pending
- 2016-06-08 MY MYPI2017704814A patent/MY184266A/en unknown
- 2016-06-08 BR BR112017023374-6A patent/BR112017023374A2/pt active Search and Examination
- 2016-06-08 CN CN201680034297.0A patent/CN107787229A/zh active Pending
- 2016-06-08 NZ NZ73704616A patent/NZ737046A/en unknown
- 2016-06-08 EA EA201792359A patent/EA037580B1/ru not_active IP Right Cessation
- 2016-06-08 AU AU2016280555A patent/AU2016280555B2/en active Active
- 2016-06-08 JP JP2017564734A patent/JP6438599B2/ja active Active
- 2016-06-08 MX MX2017016199A patent/MX2017016199A/es unknown
- 2016-06-08 IL IL292562A patent/IL292562A/en unknown
- 2016-06-08 UA UAA201712093A patent/UA120881C2/uk unknown
- 2016-06-08 WO PCT/US2016/036407 patent/WO2016205037A1/en active Application Filing
-
2017
- 2017-10-27 ZA ZA2017/07324A patent/ZA201707324B/en unknown
- 2017-11-05 IL IL255443A patent/IL255443B/en unknown
-
2018
- 2018-04-26 HK HK18105442.3A patent/HK1245813A1/zh unknown
-
2021
- 2021-12-17 US US17/554,713 patent/US20220112277A1/en active Pending
-
2022
- 2022-08-08 US US17/883,072 patent/US20230159628A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114948847A (zh) | 2022-08-30 |
KR20180002858A (ko) | 2018-01-08 |
HK1245813A1 (zh) | 2018-08-31 |
US11498959B2 (en) | 2022-11-15 |
MY184266A (en) | 2021-03-30 |
US20220112277A1 (en) | 2022-04-14 |
EA037580B1 (ru) | 2021-04-16 |
AU2016280555A1 (en) | 2017-11-16 |
AU2016280555B2 (en) | 2018-11-15 |
JP2018517727A (ja) | 2018-07-05 |
NZ737046A (en) | 2019-09-27 |
KR102000867B1 (ko) | 2019-07-16 |
IL255443A0 (en) | 2017-12-31 |
IL292562A (en) | 2022-06-01 |
BR112017023374A2 (pt) | 2018-07-24 |
US20230159628A1 (en) | 2023-05-25 |
JP6438599B2 (ja) | 2018-12-19 |
CA2984185A1 (en) | 2016-12-22 |
ZA201707324B (en) | 2020-01-29 |
CN107787229A (zh) | 2018-03-09 |
MA49726A (fr) | 2020-06-10 |
UA120881C2 (uk) | 2020-02-25 |
MX2017016199A (es) | 2018-03-01 |
IL255443B (en) | 2022-06-01 |
US20180134772A1 (en) | 2018-05-17 |
TW201711697A (zh) | 2017-04-01 |
AR104847A1 (es) | 2017-08-16 |
EA201792359A1 (ru) | 2018-05-31 |
WO2016205037A1 (en) | 2016-12-22 |
TWI725973B (zh) | 2021-05-01 |
EP3310809A1 (en) | 2018-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3772B1 (ar) | صيغة جسم مضاد لـ cgrp | |
MX2022003891A (es) | Anticuerpos anti-muc16 y sus usos. | |
PH12017500861A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
ZA201806576B (en) | Antibodies, pharmaceutical compositions and methods | |
MY191581A (en) | Anti-pd-1 antibodies | |
PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
MX2019007020A (es) | Anticuerpos il-11. | |
PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
SG10201803042PA (en) | Anti-tim-3 antibodies | |
MX2019007021A (es) | Anticuerpos il-11ra. | |
PH12017500322A1 (en) | Anti-her2 antibodies and immunoconjugates | |
MX2021010471A (es) | Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr. | |
MX2017003022A (es) | Anticuerpos anti-cll-1 e inmunoconjugados. | |
MX2017007941A (es) | Anticuerpos antagonistas anti-axl. | |
EA201691991A1 (ru) | Мультиспецифические антитела | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
PH12018501043A1 (en) | Site specific her2 antibody drug conjugates | |
MX2017016169A (es) | Anticuerpos anti-her2 y metodos de uso. | |
TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
MX2016015162A (es) | Anticuerpos anti - gpc3 e inmunoconjugados. | |
MY191539A (en) | Streptococcal vaccine | |
MX2017000527A (es) | Formulaciones de anticuerpos cristalinos. | |
IN2014MU01248A (ar) | ||
MX2021006003A (es) | Formulaciones de anticuerpos cristalinos. | |
MX2016016233A (es) | Anticuerpos anti-lgr5 y sus usos. |